Table 2

Physical parameters values at baseline and following 15 weeks of double-blind treatment

PS-DHA

Placebo


Variable

Baseline (mean ± SD)

15 weeks (mean ± SD)

P value1 (within group)

Baseline (mean ± SD)

15 weeks (mean ± SD)

P value1 (within group)

P value2 (between groups)

Resting systolic BP (mm Hg)

127.1 ± 13.4

128.4 ± 15.4

0.511

127.6 ± 15.8

127.8 ± 16.5

0.909

0.685


Male

125.4 ± 13.5

126.8 ± 14.6

0.612

129.0 ± 13.0

131.7 ± 12.6

0.244

0.691


Female

128.8 ± 13.3

130.0 ± 16.2

0.676

126.1 ± 18.7

123.3 ± 19.5

0.330

0.331


Resting diastolic BP (mm Hg)

73.8 ± 9.2

72.6 ± 9.1

0.299

75.0 ± 7.9

73.3 ± 9.4

0.159

0.746


Male

73.9 ± 9.3

71.7 ± 9.0

0.188

75.4 ± 8.0

73.9 ± 9.7

0.289

0.795


Female

73.6 ± 9.2

73.4 ± 9.3

0.893

74.6 ± 7.8

72.7 ± 9.2

0.357

0.516


Resting pulse (beats/minute)

69.4 ± 10.1

69.9 ± 9.5

0.657

66.5 ± 8.4

67.6 ± 10.1

0.394

0.725


Male

69.1 ± 11.8

69.8 ± 10.8

0.648

63.9 ± 7.8

66.1 ± 10.1

0.139

0.482


Female

69.7 ± 8.4

69.9 ± 8.2

0.872

69.6 ± 8.2

69.3 ± 9.6

0.865

0.812


Weight (kg)

70.3 ± 11.2

70.8 ± 11.6

0.033*

73.0 ± 12.9

73.3 ± 13.3

0.209

0.622


Male

77.4 ± 9.6

78.0 ± 9.9

0.036*

79.1 ± 11.1

79.5 ± 11.5

0.235

0.664


Female

63.7 ± 8.3

64.0 ± 8.7

0.359

66.1 ± 11.4

66.3 ± 11.9

0.640

0.746


1 Based on two-sided t test for dependent samples. 2 Based on two-sided t test for independent samples

* Statistical significance was not maintained following Bonferonni correction

In the treatment arm, 32 males and 33 females had blood pressure and pulse measurements at baseline and endpoint and 31 males and 33 females had weight measurements at baseline and endpoint. In the placebo arm, 34 males and 29 females had blood pressure and pulse measurements at baseline and endpoint and 33 males and 29 females had weight measurements at baseline and endpoint.

Vakhapova et al. BMC Neurology 2011 11:79   doi:10.1186/1471-2377-11-79

Open Data